US 2023/0057263 A1 · SINGLE-AND MULTI-CHAIN POLYPEPTIDES THAT BIND SPECIFICALLY TO CD3 EPSILON

Abstract

Provided herein are single-chain polypeptides and multi-chain polypeptides that bind specifically to CD3 epsilon (CD3ε). Also provided herein are anti-idiotypic antibodies that bind specifically to any of the antigen-binding domains described herein.

Claims31

Dependent claims

1-75. (canceled)

A multi-chain polypeptide comprising:

(a) a first polypeptide comprising a light chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO:
1, and a second polypeptide comprising a heavy chain variable domain comprising an amino acid sequence at least 92% identical to SEQ ID NO:
3;
(b) a first polypeptide comprising a light chain variable domain comprising an amino acid sequence at least 96% identical to SEQ ID NO:
8, and a second polypeptide comprising a heavy chain variable domain comprising an amino acid sequence at least 92% identical to SEQ ID NO:
10;
(c) a first polypeptide comprising a light chain variable domain comprising an amino acid sequence at least 96% identical to SEQ ID NO:
12, and a second polypeptide comprising a heavy chain variable domain comprising an amino acid sequence at least 90% identical to SEQ ID NO:
14;
(d) a first polypeptide comprising a light chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO:
26, and a second polypeptide comprising a heavy chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO:
115;
(e) a first polypeptide comprising a light chain variable domain comprising at least 95% identical to SEQ ID NO:
1, and a second polypeptide comprising a heavy chain variable domain comprising at least 95% identical to SEQ ID NO:
5;
(f) a first polypeptide comprising a light chain variable domain comprising at least 95% identical to SEQ ID NO:
1, and a second polypeptide comprising a heavy chain variable domain comprising at least 95% identical to SEQ ID NO:
6;
(g) a first polypeptide comprising a light chain variable domain comprising at least 95% identical to SEQ ID NO:
1, and a second polypeptide comprising a heavy chain variable domain comprising at least 95% identical to SEQ ID NO:
7;
(h) a first polypeptide comprising a light chain variable domain comprising at least 92% identical to SEQ ID NO:
16, and a second polypeptide comprising a heavy chain variable domain comprising at least 90% identical to SEQ ID NO:
18;
(i) a first polypeptide comprising a light chain variable domain comprising a sequence of SEQ ID NO:
1, and a second polypeptide comprising a heavy chain variable domain comprising a sequence of SEQ ID NO:
3;
(j) a first polypeptide comprising a light chain variable domain comprising a sequence of SEQ ID NO:
8, and a second polypeptide comprising a heavy chain variable domain comprising a sequence of SEQ ID NO:
10;
(k) a first polypeptide comprising a light chain variable domain comprising a sequence of SEQ ID NO:
12, and a second polypeptide comprising a heavy chain variable domain comprising a sequence of SEQ ID NO:
14;
(l) a first polypeptide comprising a light chain variable domain comprising a sequence of SEQ ID NO:
26, and a second polypeptide comprising a heavy chain variable domain comprising a sequence of SEQ ID NO:
115;
(m) a first polypeptide comprising a light chain variable domain comprising a sequence of SEQ ID NO:
1, and a second polypeptide comprising a heavy chain variable domain comprising a sequence of SEQ ID NO:
5;
(n) a first polypeptide comprising a light chain variable domain comprising a sequence of SEQ ID NO:
1, and a second polypeptide comprising a heavy chain variable domain comprising a sequence of SEQ ID NO:
6;
(o) a first polypeptide comprising a light chain variable domain comprising a sequence of SEQ ID NO:
1, and a second polypeptide comprising a heavy chain variable domain comprising a sequence of SEQ ID NO:
7;
or
(p) a first polypeptide comprising a light chain variable domain comprising a sequence of SEQ ID NO:
16, and a second polypeptide comprising a heavy chain variable domain comprising a sequence of SEQ ID NO:
18;
wherein the light chain variable domain and the heavy chain variable domain form an antigen-binding domain that binds specifically to CD3 epsilon.

47 more elements

A single-chain polypeptide comprising:

(a) a light chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO:
1, and a heavy chain variable domain comprising an amino acid sequence at least 92% identical to SEQ ID NO:
3;
(b) a light chain variable domain comprising an amino acid sequence at least 96% identical to SEQ ID NO:
8, and a heavy chain variable domain comprising an amino acid sequence at least 92% identical to SEQ ID NO:
10;
(c) a light chain variable domain comprising an amino acid sequence at least 96% identical to SEQ ID NO:
12, and a heavy chain variable domain comprising an amino acid sequence at least 90% identical to SEQ ID NO:
14;
(d) a light chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO:
26, and an amino acid heavy chain variable domain comprising a sequence at least 95% identical to SEQ ID NO:
115;
(e) a light chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO:
1, and a heavy chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO:
5;
(f) a light chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO:
1, and a heavy chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO:
6;
(g) a light chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO:
1, and a heavy chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO:
7;
(h) a light chain variable domain comprising an amino acid sequence at least 92% identical to SEQ ID NO:
16, and a heavy chain variable domain comprising an amino acid sequence at least 90% identical to SEQ ID NO:
18;
(i) a light chain variable domain comprising an amino acid sequence of SEQ ID NO:
1, and a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO:
3;
(j) a light chain variable domain comprising an amino acid sequence of SEQ ID NO:
8, and a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO:
10;
(k) a light chain variable domain comprising an amino acid sequence of SEQ ID NO:
12, and a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO:
14;
(l) a light chain variable domain comprising an amino acid sequence of SEQ ID NO:
26, and a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO:
115;
(m) a light chain variable domain comprising an amino acid sequence of SEQ ID NO:
1, and a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO:
5;
(n) a light chain variable domain comprising an amino acid sequence of SEQ ID NO:
1, and a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO:
6;
(o) a light chain variable domain comprising an amino acid sequence of SEQ ID NO:
1, and a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO:
7;
or
(p) a light chain variable domain comprising an amino acid sequence of SEQ ID NO:
16, and a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO:
18;
wherein the light chain variable domain and the heavy chain variable domain form an antigen-binding domain that binds specifically to CD3 epsilon.

47 more elements

An anti-idiotypic antibody comprising:

(a) a first polypeptide comprises a light chain variable domain comprising an amino acid sequence at least 96% identical to SEQ ID NO:
27, and a second polypeptide comprising a heavy chain variable domain comprising an amino acid sequence at least 90% identical to SEQ ID NO:
29;
(b) a first polypeptide comprises a light chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO:
38, and a second polypeptide comprising a heavy chain variable domain comprising an amino acid sequence at least 90% identical to SEQ ID NO:
40;
(c) a first polypeptide comprises a light chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO:
31, and a second polypeptide comprising a heavy chain variable domain comprising an amino acid sequence at least 90% identical to SEQ ID NO:
33;
(d) a first polypeptide comprises a light chain variable domain comprising an amino acid sequence at least 99% identical to SEQ ID NO:
42, and a second polypeptide comprising a heavy chain variable domain comprising an amino acid sequence at least 90% identical to SEQ ID NO:
44;
(e) a first polypeptide comprises a light chain variable domain comprising an amino acid sequence at least 99% identical to SEQ ID NO:
42, and a second polypeptide comprising a heavy chain variable domain comprising an amino acid sequence at least 90% identical to SEQ ID NO:
48;
(f) a first polypeptide comprises a light chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO:
31, and a second polypeptide comprising a heavy chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO:
36;
(g) a first polypeptide comprises a light chain variable domain comprising an amino acid sequence at least 99% identical to SEQ ID NO:
42, and a second polypeptide comprising a heavy chain variable domain comprising an amino acid sequence at least 90% identical to SEQ ID NO:
46;
(h) a first polypeptide comprising a light chain variable domain comprising a sequence of SEQ ID NO:
27, and a second polypeptide comprising a heavy chain variable domain comprising a sequence of SEQ ID NO:
29;
(i) a first polypeptide comprising a light chain variable domain comprising a sequence of SEQ ID NO:
38, and a second polypeptide comprising a heavy chain variable domain comprising a sequence of SEQ ID NO:
40;
(j) a first polypeptide comprising a light chain variable domain comprising a sequence of SEQ ID NO:
31, and a second polypeptide comprising a heavy chain variable domain comprising a sequence of SEQ ID NO:
33;
(k) a first polypeptide comprising a light chain variable domain comprising a sequence of SEQ ID NO:
42, and a second polypeptide comprising a heavy chain variable domain comprising a sequence of SEQ ID NO:
44;
(l) a first polypeptide comprising a light chain variable domain comprising a sequence of SEQ ID NO:
42, and a second polypeptide comprising a heavy chain variable domain comprising a sequence of SEQ ID NO:
48;
(m) a first polypeptide comprising a light chain variable domain comprising a sequence of SEQ ID NO:
31, and a second polypeptide comprising a heavy chain variable domain comprising a sequence of SEQ ID NO:
36;
or
(n) a first polypeptide comprising a light chain variable domain comprising a sequence of SEQ ID NO:
42, and a second polypeptide comprising a heavy chain variable domain comprising a sequence of SEQ ID NO:
46;
wherein the light chain variable domain and the heavy chain variable domain form an antigen-binding domain that binds specifically to a CD3 epsilon antibody.

41 more elements

Dependencies are inferred from the claim text.

Facts

Application

17/790,825Filed 6 Jan 2021

Priority

6 Jan 2020

Published

23 Feb 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification9 codes

C07K 16/2809
Against the immunoglobulin superfamily: against the T-cell receptor -CD3 complex
C07K 16/4208
Against immunoglobulins: against an idiotypic determinant on Ig
C07K 16/4241
Against an idiotypic determinant on Ig: against anti-human or anti-animal Ig
C07K 2317/33
Characterized by aspects of specificity or valency: crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Single-and multi-chain polypeptides that bind specifically to cd3 epsilon

Life of this patent

Abstract

Claims31

Single-and multi-chain polypeptides that bind specifically to cd3 epsilon

Life of this patent

Abstract

Claims31